No Data
No Data
Canopy Growth Posts Wider-than-expected Loss as Revenue Falls, but Company Sees Growth Opportunities in U.S. Markets
Express News | Cronos Group Inc : BofA Global Research Cuts Price Objective to $2.30 From $2.75
Cronos Group: Caution Advised Amid Regulatory Uncertainties and Sector Re-rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cronos Group (CRON), Relay Therapeutics (RLAY) and Century Therapeutics (IPSC)
Why Investors Were High on Cronos Group Today
Earnings Call Summary | Cronos Group(CRON.US) Q2 2024 Earnings Conference